Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.drudis.2020.06.017 http://scihub22266oqcxt.onion/10.1016/j.drudis.2020.06.017 32574699!7305878!32574699     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Drug+Discov+Today 2020 ; 25 (8): 1535-1544 Nephropedia Template TP {{tp|p=32574699|t=2020. Discovering small-molecule therapeutics against SARS-CoV-2 |pdf=|usr=}}{{32574699}} gab.com Text Discovering small-molecule therapeutics against SARS-CoV-2 JO: Drug Discov Today http://www.kidney.de/pget.php?&tw=1&pmid=32574699 #FOAvip Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly become a global health pandemic. The lack of effective treatments, coupled with its etiology, has resulted in more than 400,000 deaths at the time of writing. The SARS-CoV-2 genome is highly homologous to that of SARS-CoV, the causative agent behind the 2003 SARS outbreak. Based on prior reports, clinicians have pursued the off-label use of several antiviral drugs, while the scientific community has responded by seeking agents against traditional targets, especially viral proteases. However, several avenues remain unexplored, including disrupting E and M protein oligomerization, outcompeting host glycan-virus interactions, interfering with the heparan sulfate proteoglycans-virus interaction, and others. In this review, we highlight some of these opportunities while summarizing the drugs currently in use against coronavirus 2019 (COVID-19). Twit Text FOAVip Discovering small-molecule therapeutics against SARS-CoV-2 ????Drug Discov Today http://www.kidney.de/pget.php?&tw=1&pmid=32574699 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32574699 #FOAvip English Wikipedia <ref>{{Cite pmid|32574699}}</ref> Discovering small-molecule therapeutics against SARS-CoV-2 #MMPMID32574699 Tiwari V; Beer JC; Sankaranarayanan NV; Swanson-Mungerson M; Desai UR Drug Discov Today 2020[Aug]; 25 (8): 1535-1544 PMID32574699show ga Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly become a global health pandemic. The lack of effective treatments, coupled with its etiology, has resulted in more than 400,000 deaths at the time of writing. The SARS-CoV-2 genome is highly homologous to that of SARS-CoV, the causative agent behind the 2003 SARS outbreak. Based on prior reports, clinicians have pursued the off-label use of several antiviral drugs, while the scientific community has responded by seeking agents against traditional targets, especially viral proteases. However, several avenues remain unexplored, including disrupting E and M protein oligomerization, outcompeting host glycan-virus interactions, interfering with the heparan sulfate proteoglycans-virus interaction, and others. In this review, we highlight some of these opportunities while summarizing the drugs currently in use against coronavirus 2019 (COVID-19). |Animals[MESH] |Antiviral Agents/pharmacology/*therapeutic use[MESH] |Betacoronavirus/drug effects/isolation & purification[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Coronavirus Infections/*drug therapy/virology[MESH] |Drug Discovery[MESH] |Humans[MESH] |Off-Label Use[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/virology[MESH]Discovering small-molecule therapeutics against SARS-CoV-2 (epmc).pdf DeepDyve Pubget Overpricing